Comparing high‐dose cisplatin with cisplatin‐based combination chemotherapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous cell carcinoma (LAHNSCC)

BACKGROUND: High‐dose cisplatin (Cis) is a preferred systemic agent for concurrent chemoradiation (CRT) in locally advanced head and neck squamous cell cancer (LAHNSCC) patients. As some patients are unable to tolerate Cis, this study compares the toxicity and efficacy of weekly cisplatin‐paclitaxel...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Med
Main Authors: Furqan, Muhammad, Snyders, Travis P., Saqlain, Mohammed U., Mott, Sarah L., Laux, Douglas, Snow, Anthony, Anderson, Carryn M., Watkins, John M., Clamon, Gerald H.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Clinical Cancer Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6558467/
https://ncbi.nlm.nih.gov/pubmed/30968604
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2139
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados